Archive for March, 2012

What Every Biotech Entrepreneur Needs to Know about VC Due Diligence

Due diligence, as it applies to venture capital, is actually imprecise. Origins of the term are based in banking case law. Due diligence to the attorney is more of a precise concept. A better term is “homework.” Better indeed, because the burden of…


Building Teams in Entrepreneurial Companies

This article focuses on the essentials of building effective, collaborative, team-based organizations. The entrepreneurs and innovators who found and build technology-based organizations comprise out target audience, but most specifically we address th…


Partnering With the NIH: Now Part of the “Value Proposition” for Start-ups

For many years the United States has led the world in government support for non-military research and development (R&D), especially support for work that directly relates to health and human development.  A focal point for such federal investment…


Strategic Engagement of the Science-Business Media

As surely as the bio-enterprise can benefit from positive media coverage, it cannot thrive in the face of unanswered negative and/or inaccurate media attention. On all counts, the bio-enterprise must be able to strategically engage with the media at ev…


The Basics of Coverage, Coding, and Reimbursement

The process of commercializing a new item or service in the U.S. health care market involves three distinct but necessary components: coverage, coding, and reimbursement.  This article provides an overview of these processes and the challenges in succ…


Valuation Methods in Early-Stage Biotechnology Enterprises: The “Venture Capital Method” at Work

Valuation approaches to biotechnology companies by angel investors and venture capitalists often appear to the entrepreneurs to be based on voodoo rather than sound principles of finance. While there may be some truth to that perception, there is actua…